Assembly Biosciences (Nasdaq: ASMB) is a biopharmaceutical company developing innovative treatments for hepatitis B virus infection (HBV) and C. difficile-associated diarrhea (CDAD). Both programs have breakthrough potential to provide higher cure rates for these debilitating diseases.
Assembly Biosciences is committed to advancing science and enhancing the health and well-being of patients. This commitment, along with a vibrant team culture, drives our efforts to develop and commercialize novel approaches to treating HBV and CDAD.
© 2016 Assembly Biosciences